Table 2.
Relapses and survival in randomized controlled trials in stage 1 seminoma
| Reference/No. of patients | Treatment | Total relapses | No. pelvic relapses | Relapse-free survival | Other |
|---|---|---|---|---|---|
| [44] n = 625 |
20 Gy RT (n = 313) | 11 | 3 | At 2 years: 97% | 8/9 pelvic relapses occurred in the PA RT field group |
| 30 Gy RT (n = 312) | 10 | 6 | At 5 years: 97%* | ||
| [43] n = 478 |
DL RT (n = 242) | 9 | 0 | At 3 years: 96.6% At 5 years: 96.2%* | 3-years OS: 100% |
| PA RT (n = 236) | 9 | 4 | At 3 years: 96% At 5 years: 96.1%* | 3-years OS: 99.3% | |
| [18,58] n = 1477 |
RT: PA or DL, 20 or 30 Gy (n = 904) | 36 | 10 | At 3 years: 95.9% At 5 years: 96%* | - All pelvic relapses occurred in the PA RT group - 74% of relapses in the carboplatin group occurred in the PA nodes |
| 1 cycle carboplatin (n = 573) | 29 | 0 | At 3 years: 94.8% At 5 years: 94.7%* | ||
RT: radiation therapy; DL: Dog-Leg; PA: para-aortic; OS: overall survival;* data retrieved in update.